Marcelo V Negrao - JoVE Visualize

Showing results (31-40 of 58) with videos related to

Pageof 6

Sort By:

The Journal of Thoracic and Cardiovascular Surgery|February 22, 2022

Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancerBoris Sepesi, Nicolas Zhou, William N William, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 20, 2018

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLCXiuning Le, Sonam Puri, Marcelo V Negrao, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 28, 2023

Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLCKaiwen Wang, Robyn Du, Nathaniel J Myall, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 6, 2025

Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief ReportGregory J Riely, Myung-Ju Ahn, Jeffrey M Clarke, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 19, 2020

STING Pathway Expression Identifies NSCLC With an Immune-Responsive PhenotypeCarminia M Della Corte, Triparna Sen, Carl M Gay, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 17, 2020

Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver MutationsMarcelo V Negrao, Victoria M Raymond, Richard B Lanman, et al.

Journal for Immunotherapy of Cancer|July 4, 2023

Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trialMehmet Altan, Yan Wang, Juhee Song, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2025

First-line MET tyrosine kinase inhibitors versus immunotherapy ± chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLCFederica Pecci, Hui Li, Alessandro Di Federico, et al.

Cancer Cell|July 12, 2022

Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivityYasir Y Elamin, Jacqulyne P Robichaux, Brett W Carter, et al.

Journal for Immunotherapy of Cancer|February 3, 2022

Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytesParin Shah, Marie-Andrée Forget, Meredith L Frank, et al.

Pageof 6

Showing results (31-40 of 58) with videos related to

Sort By:

Pageof 6

The Journal of Thoracic and Cardiovascular Surgery|February 22, 2022

Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancerBoris Sepesi, Nicolas Zhou, William N William, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 20, 2018

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLCXiuning Le, Sonam Puri, Marcelo V Negrao, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 28, 2023

Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLCKaiwen Wang, Robyn Du, Nathaniel J Myall, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 6, 2025

Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief ReportGregory J Riely, Myung-Ju Ahn, Jeffrey M Clarke, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 19, 2020

STING Pathway Expression Identifies NSCLC With an Immune-Responsive PhenotypeCarminia M Della Corte, Triparna Sen, Carl M Gay, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 17, 2020

Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver MutationsMarcelo V Negrao, Victoria M Raymond, Richard B Lanman, et al.

Journal for Immunotherapy of Cancer|July 4, 2023

Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trialMehmet Altan, Yan Wang, Juhee Song, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2025

First-line MET tyrosine kinase inhibitors versus immunotherapy ± chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLCFederica Pecci, Hui Li, Alessandro Di Federico, et al.

Cancer Cell|July 12, 2022

Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivityYasir Y Elamin, Jacqulyne P Robichaux, Brett W Carter, et al.

Journal for Immunotherapy of Cancer|February 3, 2022

Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytesParin Shah, Marie-Andrée Forget, Meredith L Frank, et al.

Pageof 6